Transcept Pharmaceuticals, Inc.(Nasdaq: TSPT ) plummeted today to a year low. Pharmaceutical company said it expects a second rejection letter from the U.S. health regulator regarding its sleep disorder drug. Transcept expects complete response letter on Intermezzo NDA Transcept Pharmaceuticals announced that it expects to receive a complete response letter from the U.S. FDA regarding […]